Immunotherapies for hepatocellular carcinoma

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

(2021) Carl M. Gay et al.   CANCER CELL

IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

(2021) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression of NKG2D ligands is downregulated by beta-catenin signaling and associates with HCC aggressiveness

(2021) Mathilde CADOUX et al.   JOURNAL OF HEPATOLOGY

Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination

(2021) Jiali Yu et al.   NATURE MEDICINE

Hepatocellular carcinoma

(2021) Josep M. Llovet et al.   Nature Reviews Disease Primers

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

(2021) A. Vogel et al.   ANNALS OF ONCOLOGY

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

(2021) Kevin Litchfield et al.   CELL

Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis

(2021) Cathrin LC. Gudd et al.   JOURNAL OF HEPATOLOGY

Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

(2021) Josep M. Llovet et al.   Nature Reviews Gastroenterology & Hepatology

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

(2021) David J. Pinato et al.   BMC CANCER

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

(2021) Dominik Pfister et al.   NATURE

Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH

(2021) Michael Dudek et al.   NATURE

Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes

(2021) Zowi R. Huinen et al.   Nature Reviews Clinical Oncology

O-1 Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma

(2021) M. Ducreux et al.   ANNALS OF ONCOLOGY

Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020)

(2021) Philipp K. Haber et al.   GASTROENTEROLOGY

Immunomodulatory effects of lenvatinib plus anti‐PD1 in mice and rationale for patient enrichment in hepatocellular carcinoma

(2021) Laura Torrens et al.   HEPATOLOGY

IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor).

(2021) Michel Ducreux et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.

(2021) Philipp K. Haber et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

(2021) Robin Kate Kelley et al.   JOURNAL OF CLINICAL ONCOLOGY

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

(2021) Shukui Qin et al.   JOURNAL OF CLINICAL ONCOLOGY

CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis

(2021) Masatoshi Kudo et al.   JOURNAL OF HEPATOLOGY

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

(2021) Zhenggang Ren et al.   LANCET ONCOLOGY

Hepatitis C virus modulates signal peptide peptidase to alter host protein processing

(2021) Junki Hirano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma

(2021) Amanda J. Craig et al.   PLoS Genetics

Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice

(2021) David J. Pinato et al.   EUROPEAN JOURNAL OF CANCER

Systemic treatment of hepatocellular carcinoma: An EASL position paper

(2021) Jordi Bruix et al.   JOURNAL OF HEPATOLOGY

Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review

(2020) Thibaut d’Izarny‐Gargas et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-titer HBV Carrier Mice

(2020) Thomas Michler et al.   GASTROENTEROLOGY

Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma

(2020) Bruno Sangro et al.   JOURNAL OF HEPATOLOGY

Gut microbiome in HCC – Mechanisms, diagnosis and therapy

(2020) Robert F. Schwabe et al.   JOURNAL OF HEPATOLOGY

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

(2020) Shukui Qin et al.   LANCET ONCOLOGY

New predictors for immunotherapy responses sharpen our view of the tumour microenvironment

(2020) Tullia C. Bruno   NATURE

Neoadjuvant checkpoint blockade for cancer immunotherapy

(2020) Suzanne L. Topalian et al.   SCIENCE

Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models

(2020) Taiki Kurino et al.   Journal for ImmunoTherapy of Cancer

Energy metabolism and cell motility defect in NK-cells from patients with hepatocellular carcinoma

(2020) Alessandra Zecca et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase 1 Trials

(2020) Donghua Shi et al.   CLINICAL CANCER RESEARCH

Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference

(2020) Josep M. Llovet et al.   HEPATOLOGY

Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip

(2020) Kaku Goto et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy

(2020) Jing Li et al.   JOURNAL OF CLINICAL INVESTIGATION

Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma

(2020) Robert Montal et al.   JOURNAL OF HEPATOLOGY

Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality

(2020) Tracey G. Simon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer

(2020) Charles Dolladille et al.   JAMA Oncology

LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma

(2020) B. Sangro et al.   ANNALS OF ONCOLOGY

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Longevity and replenishment of human liver-resident memory T cells and mononuclear phagocytes

(2020) Laura J. Pallett et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

(2020) Bruno Sangro et al.   JOURNAL OF HEPATOLOGY

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

(2020) Michael S Lee et al.   LANCET ONCOLOGY

Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial

(2020) Vincenzo Mazzaferro et al.   LANCET ONCOLOGY

Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade

(2020) David J. Pinato et al.   Cancers

Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma

(2020) Laia Bassaganyas et al.   CLINICAL CANCER RESEARCH

Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a non-randomized, open-label, phase 2 trial

(2020) Jianming Xu et al.   CLINICAL CANCER RESEARCH

Cabozantinib enhances the efficacy and immune modulatory activity of anti-PD1 therapy in a syngeneic mouse model of hepatocellular carcinoma

(2020) Roger Esteban-Fabró et al.   JOURNAL OF HEPATOLOGY

Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma

(2020) Chang Gon Kim et al.   JOURNAL OF HEPATOLOGY

Qualification of tumour mutational burden by targeted next‐generation sequencing as a biomarker in hepatocellular carcinoma

(2020) Ching Ngar Wong et al.   LIVER INTERNATIONAL

Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma

(2020) Johann von Felden et al.   ONCOGENE

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study

(2020) Petros Fessas et al.   Journal for ImmunoTherapy of Cancer

Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy

(2020) David J Pinato et al.   Journal for ImmunoTherapy of Cancer

Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma

(2020) Yunfan Sun et al.   CELL

Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma

(2020) David J. Pinato et al.   HEPATOLOGY

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline

(2020) John D. Gordan et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

(2020) Thierry André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Global immune characterization of HBV/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression

(2020) Guohe Song et al.   Cell Discovery

Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice

(2020) Jordi Rimola et al.   EUROPEAN JOURNAL OF RADIOLOGY

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Translation control of the immune checkpoint in cancer and its therapeutic targeting

(2019) Yichen Xu et al.   NATURE MEDICINE

Genomic correlates of response to immune checkpoint blockade

(2019) Tanya E. Keenan et al.   NATURE MEDICINE

Neoantigen-directed immune escape in lung cancer evolution

(2019) Rachel Rosenthal et al.   NATURE

Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma

(2019) Ying Jiang et al.   NATURE

Combined locoregional-immunotherapy for liver cancer

(2019) Tim F. Greten et al.   JOURNAL OF HEPATOLOGY

Hepatocellular carcinoma in the setting of alcohol-related liver disease

(2019) Nathalie Ganne-Carrié et al.   JOURNAL OF HEPATOLOGY

Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy

(2019) Anthony Tanoto Tan et al.   GASTROENTEROLOGY

The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma

(2019) David Agdashian et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study

(2019) David J. Pinato et al.   BRITISH JOURNAL OF CANCER

Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer

(2019) Mohsen Malehmir et al.   NATURE MEDICINE

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

(2019) Filipe Martins et al.   Nature Reviews Clinical Oncology

From NASH to HCC: current concepts and future challenges

(2019) Quentin M. Anstee et al.   Nature Reviews Gastroenterology & Hepatology

Hepatocellular Carcinoma

(2019) Augusto Villanueva   NEW ENGLAND JOURNAL OF MEDICINE

An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents

(2019) Agrin Moeini et al.   GASTROENTEROLOGY

Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival

(2019) Josep M. Llovet et al.   JOURNAL OF HEPATOLOGY

β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma

(2019) Marina Ruiz de Galarreta et al.   Cancer Discovery

Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma

(2019) Ahmed Omar Kaseb et al.   Cancer Immunology Research

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

(2019) Suzanne L. Topalian et al.   JAMA Oncology

Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma

(2019) Yi Zheng et al.   Journal for ImmunoTherapy of Cancer

Fatal Hepatic Necrosis after Nivolumab as a Bridge to Liver Transplant for HCC – Are Checkpoint Inhibitors Safe for the Pre‐Transplant Patient?

(2019) Mina F. Nordness et al.   AMERICAN JOURNAL OF TRANSPLANTATION

The Immunobiology of Hepatocellular Carcinoma in Humans and Mice: Basic Concepts and Therapeutic Implications

(2019) Jiajie Hou et al.   JOURNAL OF HEPATOLOGY

Inefficient induction of circulating TAA-specific CD8+ T-cell responses in hepatocellular carcinoma

(2019) Catrin Tauber et al.   Oncotarget

750PA phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL

(2019) D J Pinato et al.   ANNALS OF ONCOLOGY

LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

(2019) T Yau et al.   ANNALS OF ONCOLOGY

Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer

(2019) Lichun Ma et al.   CANCER CELL

Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma

(2019) Qiming Zhang et al.   CELL

Anti-drug Antibodies Against Immune Checkpoint Blockers: Impairment of drug efficacy or indication of immune activation?

(2019) Diego Enrico et al.   CLINICAL CANCER RESEARCH

Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms

(2019) Petros Fessas et al.   IMMUNOLOGY

Image-Guided Percutaneous ‎Microwave Ablation Versus Cryoablation For Hepatocellular Carcinoma In High-Risk Locations: Intermediate-Term Results

(2019) Jiahui Hu et al.   Cancer Management and Research

Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma

(2019) Sylvie Job et al.   HEPATOLOGY

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

(2019) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease

(2019) Hsiao-Yen Ma et al.   JOURNAL OF HEPATOLOGY

Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma

(2019) Liang-qing Dong et al.   JOURNAL OF HEPATOLOGY

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

(2019) David Liu et al.   NATURE MEDICINE

Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer

(2019) Jianchun Duan et al.   JAMA Oncology

Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma

(2018) Valerie Chew et al.   GUT

Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma

(2018) Chun Jye Lim et al.   GUT

Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease

(2018) Francesca Romana Ponziani et al.   HEPATOLOGY

The Immune Landscape of Cancer

(2018) Vésteinn Thorsson et al.   IMMUNITY

β-Catenin–mediated immune evasion pathway frequently operates in primary cutaneous melanomas

(2018) Jérémie Nsengimana et al.   JOURNAL OF CLINICAL INVESTIGATION

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

(2018) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2018) Peter R. Galle et al.   JOURNAL OF HEPATOLOGY

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

(2018) Andrew X Zhu et al.   LANCET ONCOLOGY

The immunology of hepatocellular carcinoma

(2018) Marc Ringelhan et al.   NATURE IMMUNOLOGY

Tissue-resident memory T cells at the center of immunity to solid tumors

(2018) Derk Amsen et al.   NATURE IMMUNOLOGY

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

(2018) Jianfeng Shen et al.   NATURE MEDICINE

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

(2018) Dai Fukumura et al.   Nature Reviews Clinical Oncology

Role of PD-1 during effector CD8 T cell differentiation

(2018) Eunseon Ahn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers

(2018) Georgia Ritchie et al.   JAMA Oncology

CCL15 recruits suppressive monocytes to facilitate immune escape and disease progression in hepatocellular carcinoma

(2018) Long-Zi Liu et al.   HEPATOLOGY

Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma

(2018) Julien Calderaro et al.   JOURNAL OF HEPATOLOGY

Molecular therapies and precision medicine for hepatocellular carcinoma

(2018) Josep M. Llovet et al.   Nature Reviews Clinical Oncology

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy

(2018) Y -P Chen et al.   ANNALS OF ONCOLOGY

Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies

(2018) James J Harding et al.   CLINICAL CANCER RESEARCH

Granulocytic myeloid-derived suppressor cell population increases with the severity of alcoholic liver disease

(2018) Miaomiao Gao et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Association Between Aspirin Use and Risk of Hepatocellular Carcinoma

(2018) Tracey G. Simon et al.   JAMA Oncology

Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features

(2017) Daniela Sia et al.   GASTROENTEROLOGY

Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy

(2017) Jingying Zhou et al.   GUT

AASLD guidelines for the treatment of hepatocellular carcinoma

(2017) Julie K. Heimbach et al.   HEPATOLOGY

Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma

(2017) Austin G. Duffy et al.   JOURNAL OF HEPATOLOGY

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity

(2017) Shabnam Shalapour et al.   NATURE

TCF1+ hepatitis C virus-specific CD8+ T cells are maintained after cessation of chronic antigen stimulation

(2017) Dominik Wieland et al.   Nature Communications

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

(2017) I. Puzanov et al.   Journal for ImmunoTherapy of Cancer

Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma

(2016) Ana L. Gomes et al.   CANCER CELL

Focal and Local: Ectopic Lymphoid Structures and Aggregates of Myeloid and Other Immune Cells in Liver

(2016) Eli Pikarsky et al.   GASTROENTEROLOGY

HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant

(2016) William S. Mason et al.   GASTROENTEROLOGY

Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features

(2016) Julien Calderaro et al.   HEPATOLOGY

Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

(2016) Herbert Tilg et al.   HEPATOLOGY

NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis

(2016) Chi Ma et al.   NATURE

Classification and characterization of microsatellite instability across 18 cancer types

(2016) Ronald J Hause et al.   NATURE MEDICINE

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

(2016) J. Liu et al.   Cancer Discovery

Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma

(2015) Joon Hyeok Lee et al.   GASTROENTEROLOGY

Liver inflammation abrogates immunological tolerance induced by Kupffer cells

(2015) Felix Heymann et al.   HEPATOLOGY

Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion

(2015) Martin Franz Sprinzl et al.   JOURNAL OF HEPATOLOGY

Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma

(2015) Shlomi Finkin et al.   NATURE IMMUNOLOGY

Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells

(2015) Laura J Pallett et al.   NATURE MEDICINE

Metabolic Activation of Intrahepatic CD8+ T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with Hepatocytes

(2014) Monika Julia Wolf et al.   CANCER CELL

Development of Hong Kong Liver Cancer Staging System With Treatment Stratification for Patients With Hepatocellular Carcinoma

(2014) Thomas Yau et al.   GASTROENTEROLOGY

Innate and adaptive immune responses in HCV infections

(2014) Markus H. Heim et al.   JOURNAL OF HEPATOLOGY

Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment

(2014) E. Horwitz et al.   Cancer Discovery

Higher Frequencies of GARP+CTLA-4+Foxp3+ T Regulatory Cells and Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Are Associated with Impaired T-Cell Functionality

(2013) S. Kalathil et al.   CANCER RESEARCH

Human CD14+CTLA-4+regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma

(2013) Yanmei Han et al.   HEPATOLOGY

Immunodominance and functional alterations of tumor-associated antigen-specific CD8+T-cell responses in hepatocellular carcinoma

(2013) Tobias Flecken et al.   HEPATOLOGY

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

(2013) Bruno Sangro et al.   JOURNAL OF HEPATOLOGY

Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome

(2013) Shin Yoshimoto et al.   NATURE

A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma

(2012) Tim F Greten et al.   BMC CANCER

Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4

(2012) Dianne H. Dapito et al.   CANCER CELL

Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma

(2012) Shao-Lai Zhou et al.   HEPATOLOGY

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

(2012) Tadashi Yokosuka et al.   JOURNAL OF EXPERIMENTAL MEDICINE

IL-10-Producing Regulatory B Cells in the Pathogenesis of Chronic Hepatitis B Virus Infection

(2012) A. Das et al.   JOURNAL OF IMMUNOLOGY

Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B

(2012) G. Sitia et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets

(2011) Bin Gao et al.   GASTROENTEROLOGY

Radiofrequency Thermal Ablation for Hepatocellular Carcinoma Stimulates Autologous NK-Cell Response

(2010) Alessandro Zerbini et al.   GASTROENTEROLOGY

Temporal Analysis of Early Immune Responses in Patients With Acute Hepatitis B Virus Infection

(2009) Claire Dunn et al.   GASTROENTEROLOGY

Chronically inflamed livers up-regulate expression of inhibitory B7 family members

(2009) Rachel Kassel et al.   HEPATOLOGY

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

(2009) Karl S. Peggs et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma

(2008) D. Y. Chiang et al.   CANCER RESEARCH

A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells

(2008) Bastian Hoechst et al.   GASTROENTEROLOGY

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma

(2008) Daniel H. Palmer et al.   HEPATOLOGY